Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Simon Blanc
Institution:
Holy Cross Hospital
Observed institutions:
Holy Cross Hospital,
Integra (United States),
Connect
ORCID:
0009-0006-9937-3553
Observed ORCID:
0009-0006-9937-3553
OpenAlex ID:
A5044935022
Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in US community oncology practices.
2024
·
Jing-Zhou Hou
, Simon Blanc
, et al.
·
Journal of Clinical Oncology
·
7
Homologous recombination repair gene mutation (HRRm) testing patterns and treatment selection from a real-world cohort of patients with metastatic castration-resistant prostate cancer (mCRPC).
2024
·
Neal D. Shore
, Christopher Craver
, et al.
·
Journal of Clinical Oncology
·
4
Real-world clinical practice gaps in timely homologous recombination repair gene mutation (HRRm) testing and poly (ADP-ribose) polymerase inhibitor (PARPi) treatment of patients with metastatic castration resistant prostate cancer (mCRPC).
2025
·
Neal D. Shore
, Anupama Vasudevan
, et al.
·
Journal of Clinical Oncology
·
3
Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients with Chronic or Small Lymphocytic Leukemia (CLL/SLL) in US Community Oncology Practices
2023
·
Jing-Zhou Hou
, Simon Blanc
, et al.
·
Blood
·
3
Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Utilization and Clinical Outcomes Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
2024
·
Jing-Zhou Hou
, Rushir Choksi
, et al.
·
Blood
·
2
PDF
Performance of comprehensive genomic profiling (CGP) versus single gene testing (SGT) in guideline-recommended biomarker selection in non-small cell lung cancer (NSCLC).
2024
·
Vivek Subbiah
, Anupama Vasudevan
, et al.
·
Journal of Clinical Oncology
·
2
PDF
Abstract P1-11-21: Dose Reduction Impacts Persistence on Abemaciclib: A Retrospective Analysis of Real-World Data From the IntegraConnect PrecisionQ De-Identified Database
2025
·
Vikram Gorantla
, Rushir Choski
, et al.
·
Clinical Cancer Research
·
1
Treatment-Emergent Cardiovascular Events Among Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Treated with Bruton's Tyrosine Kinase Inhibitors (BTKi)
2024
·
Jing-Zhou Hou
, Rushir Choksi
, et al.
·
Blood
·
1
Abstract PO2-18-01: Assessment of Initial Dosing and Dose Management of Sacituzumab Govitecan-hziy (SG) and How Dosing Practices Impact Duration of Therapy (DOT)
2024
·
Vikram Gorantla
, Erin Alwon
, et al.
·
Cancer Research
·
1
HRR testing and PARPi utilization among patients with metastatic castration resistant prostate cancer treated in the real-world setting.
2024
·
Anupama Vasudevan
, Harvey I. Katzen
, et al.
·
Journal of Clinical Oncology
·
1
PDF
A Patient-Centered Programmatic Approach for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in the US Community Oncology Setting
2023
·
James M. Rossetti
, Rushir Choksi
, et al.
·
Blood
·
1
Comparison of molecular testing rates and biomarker positivity by histology among patients (pts) with stage IV non-small cell lung cancer (NSCLC): A quality initiative by Integra Connect PrecisionQ.
2023
·
Simon Blanc
, Mike Gart
, et al.
·
JCO Oncology Practice
·
1
PDF
Understanding differences in the rates of BRCA/HRD testing and treatment in 1st line maintenance in patients with ovarian cancer treated by gynecologic oncologists compared to other providers: A quality initiative by Integra Connect (IC) PrecisionQ.
2023
·
Fred J. Kudrik
, Mike Gart
, et al.
·
Journal of Clinical Oncology
·
1
Phenotypic differences related to homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) treated in routine care settings in the United States (US).
2023
·
Arthur Sillah
, Gboyega Adeboyeje
, et al.
·
Journal of Clinical Oncology
·
1
Abstract P5-02-43: Incidence of HER2-low Expression in HR-positive/HER2-negative and Triple-Negative Breast Cancers in the Integra Connect Database
2023
·
Marielle Fares
, Mike Gart
, et al.
·
Cancer Research
·
1
Extramedullary Involvement of the Breast by Systemic Multiple Myeloma as the Initial Presentation of Plasma Cell Myeloma: A Rare Case
2026
·
Natalia Correa
, Maya Kumar
, et al.
·
Archives of Breast Cancer
PDF
Abstract P2-12-15: Trends in Antiemetic Use in Patients Receiving Fam-trastuzumab Deruxtecan-nxki for Metastatic Breast Cancer: A Retrospective Analysis of Data from the IntegraConnect PrecisionQ De-Identified Database
2025
·
Stephan Rosenfeld
, Vikram Gorantla
, et al.
·
Clinical Cancer Research
Abstract P1-07-16: Real-World Duration of Sacituzumab Govitecan-hziy Treatment in Patients with Metastatic Triple-Negative Breast Cancer
2025
·
Fred Kudrik
, Vikram Gorantla
, et al.
·
Clinical Cancer Research
Abstract P1-11-28: Time to Next Treatment of Abemaciclib Plus Endocrine Therapy in Early-Stage High Risk HR+/HER2- Breast Cancer: A Retrospective Analysis of Real-World Data From the IntegraConnect PrecisionQ De-Identified Database
2025
·
Vikram Gorantla
, Rushir Choski
, et al.
·
Clinical Cancer Research
Abstract P3-09-25: Fam-trastuzumab Deruxtecan-nxki Versus Chemotherapy as Post-Chemotherapy Treatment in Patients with HER2-Low Metastatic Breast Cancer: An Analysis Of Real-World Data from the IntegraConnect PrecisionQ De-Identified Database
2025
·
Stephan Rosenfeld
, Vikram Gorantla
, et al.
·
Clinical Cancer Research
Abstract P1-01-15: Assessing BRCA1/2 Testing in Breast Cancer Patients: A Retrospective Analysis of Real-World Data From the IntegraConnect PrecisionQ De-Identified Database
2025
·
Fred Kudrik
, Rushir Choski
, et al.
·
Clinical Cancer Research
Patterns in maintenance therapy use in advanced ovarian cancer patients: Real-world data analysis
2024
·
Sarah Taylor
, Michael Gart
, et al.
·
Gynecologic Oncology
BRCA and homologous recombination repair deficiency testing in advanced ovarian cancer: A real-world data analysis
2024
·
Sarah Taylor
, Michael Gart
, et al.
·
Gynecologic Oncology
Real-world BRCA1/2 and homologous recombination deficiency testing dynamics and time to treatment discontinuation on PARP inhibitor first-line maintenance among patients with epithelial ovarian cancer
2024
·
Rebecca Previs
, Alison Roos
, et al.
·
Gynecologic Oncology
A quality initiative focused on BRCA and HRD testing and use of first line maintenance in advanced ovarian cancer.
2024
·
Mike Gart
, Teena Sura
, et al.
·
JCO Oncology Practice
PDF
Show more works
View as search
Works count:
47
Citation count:
30
H-index:
3
I10-index:
Year
Topic
Type